Montanez Kathleen, Berninger Taylor, Willis Mary, Harding Aaron, Lutgendorf Monica A
Department of Obstetrics and Gynecology, Naval Medical Center San Diego, San Diego, California.
UC San Diego Health, San Diego, California.
J Genet Couns. 2020 Dec;29(6):1186-1191. doi: 10.1002/jgc4.1285. Epub 2020 May 1.
We sought to determine the costs of genetic testing and compliance with published guidelines and clinical best practices at our institution. A cost analysis was performed comparing the costs of ordered tests to the cost of the recommended testing. This was an approved quality improvement project at a tertiary teaching hospital in California. We identified charts associated with the genetic testing billing codes for common genetic tests through our contracted laboratory (cystic fibrosis genotyping, Breast cancer susceptibility gene (BRCA 1&2), Methylenetetrahydrofolate reductase (MTHFR), factor V Leiden (FVL), prothrombin gene pathogenic variant, alpha-thalassemia, hemochromatosis, and cell-free fetal DNA). Charts were reviewed retrospectively by a licensed, certified genetic counselor to assess the compliance with published clinical practice guidelines identified on GeneReviews and the American College of Obstetricians and Gynecologists (ACOG). Tests were classified as: appropriate, misordered/not indicated, misordered/false reassurance, and misordered/inadequate. We performed a cost analysis for the recommended test changes. We reviewed 114 charts over a three-month period. Forty-four (38.6%) of the tests were misordered based on published clinical practice guidelines: 24 (21%) were misordered/not indicated, 8 (7%) were misordered/false reassurance, and 12 (10.5%) were misordered/inadequate. Costs of ordered testing ($75,177) were compared to recommended testing after review ($54,265), with a total cost savings of $20,912. In clinical practice, over one-third of genetic tests reviewed were misordered. As these tests are a small fraction of all genetic tests at our institution, future studies should broaden the scope of testing evaluated to understand the magnitude of this problem and potential cost savings. Genetic counselor review and involvement in genetic test ordering can decrease inappropriate healthcare expenditures and improve patient care.
我们试图确定在我们机构进行基因检测的成本,以及是否符合已发表的指南和临床最佳实践。进行了一项成本分析,将所订购检测的成本与推荐检测的成本进行比较。这是加利福尼亚州一家三级教学医院批准的质量改进项目。我们通过我们的签约实验室确定了与常见基因检测的基因检测计费代码相关的病历(囊性纤维化基因分型、乳腺癌易感基因(BRCA 1和2)、亚甲基四氢叶酸还原酶(MTHFR)、凝血因子V莱顿(FVL)、凝血酶原基因致病变异、α地中海贫血、血色素沉着症和游离胎儿DNA)。一名有执照、有认证的遗传咨询师对病历进行回顾性审查,以评估是否符合在《基因评论》和美国妇产科医师学会(ACOG)上确定的已发表临床实践指南。检测被分类为:适当、订购错误/未指明、订购错误/错误安慰和订购错误/不充分。我们对推荐的检测变更进行了成本分析。我们在三个月的时间里审查了114份病历。根据已发表的临床实践指南,44项(38.6%)检测订购错误:24项(21%)订购错误/未指明,8项(7%)订购错误/错误安慰,12项(10.5%)订购错误/不充分。将订购检测的成本(75,177美元)与审查后推荐检测的成本(54,265美元)进行比较,总成本节省了20,912美元。在临床实践中,超过三分之一的审查基因检测订购错误。由于这些检测在我们机构所有基因检测中占比很小,未来的研究应扩大评估检测的范围,以了解这个问题的严重程度和潜在的成本节省。遗传咨询师对基因检测订购的审查和参与可以减少不适当的医疗支出并改善患者护理。